About: Development and validation of an LC-MS/MS method for detection and quantification of in vivo derived metabolites of [Pyr(1)]apelin-13 in humans

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Development and validation of an LC-MS/MS method for detection and quantification of in vivo derived metabolites of [Pyr(1)]apelin-13 in humans Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : wasabi.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
has title	Development and validation of an LC-MS/MS method for detection and quantification of in vivo derived metabolites of [Pyr(1)]apelin-13 in humans
Creator	Cheriyan, Joseph Ambery, Philip Jermutus, Lutz Nyimanu, Duuamene Reimann, Frank Sulentic, Petra Davenport, Anthony Gribble, Fiona Kay, Richard Kuc, Rhoda Maguire, Janet
topic	covid:0b104ed7194e21c4ba47460db675b638b0d29bc4#this
Source	Medline; PMC
abstract	[Pyr(1)]apelin-13 is the predominant apelin peptide isoform in the human cardiovascular system and plasma. To date, few studies have investigated [Pyr(1)]apelin-13 metabolism in vivo in rats with no studies examining its stability in humans. We therefore aimed to develop an LC-MS/MS method for detection and quantification of intact [Pyr(1)]apelin-13 and have used this method to identify the metabolites generated in vivo in humans. [Pyr(1)]apelin-13 (135 nmol/min) was infused into six healthy human volunteers for 120 minutes and blood collected at time 0 and 120 minutes after infusion. Plasma was extracted in the presence of guanidine hydrochloride and analysed by LC-MS/MS. Here we report a highly sensitive, robust and reproducible method for quantification of intact [Pyr(1)]apelin-13 and its metabolites in human plasma. Using this method, we showed that the circulating concentration of intact peptide was 58.3 ± 10.5 ng/ml after 120 minutes infusion. We demonstrated for the first time that in humans, [Pyr(1)]apelin-13 was cleaved from both termini but the C-terminal was more susceptible to cleavage. Consequently, of the metabolites identified, [Pyr(1)]apelin-13((1–12)), [Pyr(1)]apelin-13((1–10)) and [Pyr(1)]apelin-13((1–6)) were the most abundant. These data suggest that apelin peptides designed for use as cardiovascular therapeutics, should include modifications that minimise C-terminal cleavage.
has issue date	2019-12-27(xsd:dateTime)
bibo:doi	10.1038/s41598-019-56157-9
bibo:pmid	31882594
has license	cc-by
sha1sum (hex)	0b104ed7194e21c4ba47460db675b638b0d29bc4
schema:url	https://doi.org/10.1038/s41598-019-56157-9
resource representing a document's title	Development and validation of an LC-MS/MS method for detection and quantification of in vivo derived metabolites of [Pyr(1)]apelin-13 in humans
has PubMed Central identifier	PMC6934825
has PubMed identifier	31882594
schema:publication	Sci Rep
resource representing a document's body	covid:0b104ed7194e21c4ba47460db675b638b0d29bc4#body_text
is http://vocab.deri.ie/void#inDataset of	proxy:http/ns.inria.fr/covid19/0b104ed7194e21c4ba47460db675b638b0d29bc4
is schema:about of	named entity 'LC-MS' named entity '120 minutes' named entity 'robust' named entity 'pyr' named entity 'pyr' named entity 'apelin' named entity 'predominant' named entity 'apelin' named entity 'DERIVED' named entity 'QUANTIFICATION' named entity 'DETECTION' named entity 'STUDIES' named entity 'HUMAN PLASMA' named entity 'EXAMINING' named entity 'LC-MS' named entity 'RATS' named entity 'TIME' named entity 'METABOLITES' named entity 'TO IDENTIFY' named entity 'METHOD' named entity 'USED' named entity '120' named entity 'ABUNDANT' named entity 'HUMAN' named entity 'STABILITY' named entity 'CONCENTRATION OF' named entity 'REPORT' named entity 'BUT' named entity 'EXTRACTED' named entity 'INFUSION' named entity 'PREDOMINANT' named entity 'DATE' named entity 'INVESTIGATED' named entity 'ROBUST' named entity 'USE' named entity 'HUMANS' named entity 'VALIDATION' named entity 'BLOOD' named entity 'PLASMA' named entity 'VOLUNTEERS' named entity 'PRESENCE OF' named entity 'CLEAVED' named entity 'GUANIDINE HYDROCHLORIDE' named entity 'HIGHLY SENSITIVE' named entity 'HEALTHY' named entity 'INTACT' named entity 'C-TERMINAL' named entity '10.5' named entity 'METABOLITES' named entity 'DEVELOPMENT' named entity 'GENERATED' named entity 'THESE' named entity 'CIRCULATING' named entity 'SUSCEPTIBLE' named entity 'APELIN' named entity 'DEMONSTRATED' named entity 'PEPTIDE' named entity 'APELIN PEPTIDES' named entity 'DATA' named entity 'DETECTION' named entity 'HUMANS' named entity 'METHOD' named entity 'IDENTIFIED' named entity 'CLEAVAGE' named entity 'ITS' named entity 'QUANTIFICATION' named entity 'CARDIOVASCULAR' named entity 'COLLECTED' named entity 'MINUTES'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software